Veterans Health Administration Is First Major Payer To Cover New Medication, Leqembi, To Delay Cognitive Impairment Of Early Alzheimer’s Disease

The U.S. Veterans' Health Administration (VHA) has approved covering Leqembi™ (lecanemab-irmb) for veterans living with early stages of Alzheimer's disease (AD), according to an announcement by Eisai, the drug’s manufacturer. VHA health care professionals meeting the criteria set forth by the VHA can prescribe Leqembi to veterans who fit the VHA's criteria and the U.S. Food and Drug Administration's (FDA) current label. The FDA approved Leqembi on January 6, 2023, under the accelerated approval pathway. Manufacturer Eisai launched U.S. sales of Leqembi on January 18, 2023. The VHA is the first major . . .